Rituximab for thyroid eye disease

Ophthalmic Plastic and Reconstructive Surgery

Volumn 26, Issue 5, 2010, Pages 310-314

  Silkiss, Rona Z ^a   Reier, Alice ^b   Coleman, Morton ^c   Lauer, Simeon A ^d  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b Summitt Medical Center   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; THYROID ANTIBODY; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; B LYMPHOCYTE; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE OPHTHALMOPATHY; FEMALE; HUMAN; INFLAMMATION; INTERVENTION STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; STRABISMUS; THYROID FUNCTION TEST; TREATMENT DURATION; VISION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; AUTOANTIBODIES; B-LYMPHOCYTES; FEMALE; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77957338955     PISSN: 07409303     EISSN: None     Source Type: Journal    
DOI: 10.1097/IOP.0b013e3181c4dfde     Document Type: Article

References (33)

1. Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 2008;18:333-46. (Pubitemid 351415802)
2. Macchia PE, Bagattini M, Lupoli G, et al. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy. J Endocrinol Invest 2001;24:152-8.
3. Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001;86:3562-7.
4. van Geest RJ, Sasim IV, Koppeschaar HP, et al. Methylpred-nisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol 2008;158:229-37.
5. Kubota S, Ohye H, Nishihara E, et al. Effect of high dose methyl-prednisolone pulse therapy followed by oral prednisolone administration on the production of anti-TSH receptor antibodies and clinical outcome in Graves' disease. Endocr J 2005;52:735-41.
6. Bradley EA, Gower EW, Bradley DJ, et al. Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2008;115:398-409.
7. Zoumalan CI, Cockerham KP, Turbin RE, et al. Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease. J Neuroophthalmol 2007; 27:205-14.
8. Wei RL, Cheng JW, Cai JP. The use of orbital radiotherapy for Graves' ophthalmopathy: quantitative review of the evidence. Ophthalmologica 2008;222:27-31.
9. Salvi M, Vannucchi G, Campi I, et al. New immunomodulators in the treatment of Graves' ophthalmopathy. Ann Endocrinol (Paris) 2008;69:153-6.
10. Bartalena L, Lai A, Compri E, et al. Novel immunomodulating agents for Graves orbitopathy. Ophthal Plast Reconstr Surg 2008; 24:251-6.
11. Nielsen CH, El Fassi D, Hegedüs L. [Novel treatment of Graves' disease using the B-lymphocyte depleting agent rituximab]. Ugeskr Laeger 2008;170:2131-4 (in Danish).
12. Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167: 4710-8.
13. Vos K, Thurlings RM, Wijbrandts CA, et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:772-8.
14. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88. (Pubitemid 351240747)
15. Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007;56:3044-56.
16. El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 2006;16:709-10.
17. El Fassi D, Nielsen CH, Bonnema SJ, et al. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 2007;92:1769-72.
18. Salvi M, Vannucchi G, Campi I, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 2006;154:511-7.
19. Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007; 156:33-40.
20. Josseaume C, Lorcy Y. [New immunomodulators in treatment of Graves' ophthalmopathy]. Ann Endocrinol (Paris) 2008;69(suppl 1): S29-32 (in French).
21. Heemstra KA, Toes RE, Sepers J, et al. Rituximab in relapsing Graves' disease, a phase II study. Eur J Endocrinol 2008;159:609 -15.
22. El Fassi D, Clemmensen O, Nielsen CH, et al. Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease. J Clin Endocrinol Metab 2007;92: 3762-3.
23. El Fassi D, Banga JP, Gilbert J, et al. Treatment with Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 2009;130:252-8.
24. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1997;47:9-14.
25. Dolman PJ, Rootman J. VISA classification for Graves orbitopa-thy. Ophthal Plast Reconstr Surg. 2006;22:319-24.
26. Conover W. Practical Nonparametric Statistics. New York, NY: John Wiley & Sons, 1980:280.
27. Statistical Analysis System, Version 9.1.3. Cary, NC: SAS Institute Inc., 2002-2008.
28. Microsoft Office Student and Teacher, Edition 2003.
29. El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L. The rationale for B lymphocyte depletion in Graves' disease: monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol 2006;154:623-32.
30. Hasselbalch HC. B-cell depletion with rituximab - a targeted therapy for Graves' disease and autoimmune thyroiditis. Immunol Lett 2003;88:85-6.
31. Takasu N, Oshiro C, Akamine H, et al. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients an in 686 normal subjects. J Endocrinol Invest 1997;20: 452-61.
32. Kazuo K, Fujikado T, Ohmi G, et al. Value of thyroid stimulating antibody in the diagnosis of thyroid associated ophthalmopathy of euthyroid patients. Br J Ophthalmol 1997;81:1080-3.
33. Noh JY, Hamada N, Inoue Y, et al. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease. Thyroid 2000;10:809-13.